Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Merck & Co., Inc. — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.28 (market cap $510.01M), while Merck & Co., Inc. trades at $145.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 688.8× GraniteShares 2x Long COIN Daily ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while GraniteShares 2x Long COIN Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Merck & Co., Inc. for 98 Days on average.
| CONL | MRK | |
|---|---|---|
Market Cap | $510.01M | $351.28B |
Volume | 21,041,836 | 7,969,665 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $156.43 |
52-Week Low | $3.93 | $82.49 |
Typical Hold Time | 15 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $5.41, up 3.44% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF, which provides 2x daily leveraged exposure to Coinbase Global stock, faces volatility from its underlying asset's performance. Recent news highlights significant price gaps and volume spikes, with the stock previously gapping up to $6.44 on October 1, 2026.
The outlook remains high-risk due to leveraged structure amplifying Coinbase's volatility. Investment opportunity exists for short-term traders betting on Coinbase rebounds, but risks include rapid decay from daily rebalancing and crypto market downturns. Long-term holders face erosion from volatility drag, requiring careful risk management.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
